Claude Science Brings AI Drug Discovery Into an Auditable Workflow

The next step for large language models in life sciences may not be automated drug invention that looks more like science fiction, but the more mundane parts of everyday laboratory work: finding literature, connecting databases, running analyses, making charts, and checking whether workflows are reproducible. That is where the significance of Anthropic’s launch of Claude Science lies. It moves AI from the chat box to the research workbench, and it also lays bare one of the most easily underestimated problems in drug discovery: scientific judgment is not a polished answer, but a series of steps that must be traceable, repeatable, and open to challenge by peers.

Anthropic announced on June 30 that Claude Science had entered beta and was available to Claude Pro, Max, Team, and Enterprise users. According to the company, the workbench integrates commonly used research tools, scientific databases, software packages, auditable artifacts, and compute resources, and includes more than 60 built-in skills and connectors for fields such as genomics, single-cell analysis, proteomics, structural biology, and cheminformatics. In other words, what it emphasizes is not a single model capability, but enabling researchers to complete data processing, molecular or protein structure visualization, genome browsing, and results organization within the same environment.

For biomedical applications, the scenarios listed by Anthropic include protein structure prediction, CRISPR screen design, cheminformatics analysis, and target nomination work conducted by Manifold Bio. These examples all fall within critical areas of early-stage R&D: researchers are trying to narrow the search space from vast and messy datasets and determine which proteins, pathways, or molecules are worth sending into the next round of experiments. If the workbench can preserve input data, analysis code, model outputs, and interim judgments, it would have practical value for team collaboration and subsequent review.

More controversial is that Anthropic reportedly does not only want to provide tools, but also intends to launch an internal drug discovery program, with directions including neglected diseases. The Verge reported that Eric Kauderer-Abrams, Anthropic’s head of life sciences, discussed the effort at an AI for Science event; The Times of India also said the company is launching an internal preclinical drug discovery program. However, the related reports also show that Anthropic has not yet clearly explained the target diseases, the subsequent development path for candidate drugs, clinical trial strategy, manufacturing arrangements, or external partners.

These gaps are critical. AI can help identify possible targets, design molecules, compare structures, or predict properties, but candidate molecules are still a long way from becoming drugs. Cell and animal experiments must confirm efficacy and mechanism, toxicology studies must rule out unacceptable risks, and human trials must demonstrate safety and efficacy; finally, regulatory review, quality control, and mass-production design are also required. The point external experts emphasized to The Verge is also this: AI can accelerate certain stages, but it cannot replace experimental validation and clinical evidence.

The commercial context is equally clear. The Financial Times reported that Claude Science is Anthropic’s first product specifically launched for scientists, and that it views pharmaceutical and research enterprise customers as potential revenue sources; its life sciences push has already involved pharmaceutical customers such as Novo Nordisk and AstraZeneca, and includes the acquisition of biotech startup Coefficient Bio. For drugmakers, if platforms of this kind can reduce the costs of data analysis and workflow management, they may enter procurement and daily use more quickly than slogans about “AI inventing miracle drugs.”

### Background Context

What is new in this wave of news is not another claim that AI can be used for drug discovery, but that large model companies are beginning to connect scientific research tools, enterprise customers, and the idea of self-developed drugs into a longer chain. If Claude Science is to gain a firm foothold in biomedical settings, it must prove that it can handle the noise, permissions, and reproducibility issues of real-world data, and it must also leave clear boundaries around model errors, data sources, and responsibility for decisions. The real dividing line will come when candidate ideas leave the screen and face experimental and regulatory scrutiny.